Document is current
Any future updates will be listed below
-
Authors
Lackner, Niklas A. https://orcid.org/0009-0001-1994-9975
Karius, Andre https://orcid.org/0000-0002-3842-1375
Brandt, Tobias
Ott, Oliver J. https://orcid.org/0000-0001-5806-6158
Putz, Florian https://orcid.org/0000-0003-3966-2872
Strnad, Vratislav https://orcid.org/0000-0002-3871-7563
May, Matthias S. https://orcid.org/0000-0002-2540-850X
Fietkau, Rainer
Bert, Christoph https://orcid.org/0000-0002-8539-6600
Szkitsak, Juliane https://orcid.org/0000-0003-4603-492X
-
Funding
Funding for this research was provided by:
NUM 2.0 (FKZ 01KX2121)
NUM 3.0 (FKZ: 01KX2524)
Universitätsklinikum Erlangen
- License Information
-
More Information
Article History
Received: 18 July 2025
Accepted: 17 November 2025
First Online: 28 November 2025
Conflict of interest
: N.A. Lackner: Vision RT Ltd., F. Putz: Siemens Healthineers AG, Brainlab AG, Astrazeneca, Servier, Working group member DEGRO, Possession of Healthcare ETF, Bavarian Cancer Center Grant, Siemens Healthineers AG Grant, Federal Ministry of Education and Research Grant, V. Strnad: Nucletron, Past-chair GEC-ESTRO, M.S. May: Siemens Healthineers AG, Bayer AG, Brainlab AG, R. Fietkau: AstraZeneca, Novocure, MSD, Siemens Healthineers, Merck Serono, Promedicis, Bristol Myers Squibb, C. Bert: Siemens Healthineers AG, President of DGMP, J. Szkitsak: Siemens Healthineers AG. A. Karius, T. Brandt and O.J. Ott declare that they have no competing interests. The Universitätsklinikum Erlangen has research agreements with Siemens Healthineers AG, Germany & Vision RT Ltd, UK. None of these agreements represent a conflict of interest relevant to this work.
